DEEP RESEARCH · INBODY
InBody 2024 Q1 Report: IR Call Memo
A follow-up note on subsidiary investment, receivables/payables, production setup, and India sales after reviewing the Q1 report
0. Bottom Line First
The key point of this call memo is not to force a final conclusion from the numbers, but to separate early-stage growth spending from accounting or working-capital changes that still need confirmation.
- BWA is a simple U.S. sales subsidiary, but because it is still in an early stage, it is consuming some investment capital.
- The increase in trade receivables and payables was not due to a change in accounting standards, but the quarter-on-quarter increase still looks large enough to ask again.
- Kort is currently small in scale and is producing through a rented portion of the Cheonan plant rather than operating a separate factory.
- The reason for the India subsidiary's sales increase remains an item to ask about.
1. Checks by Question
Early Investment Cost
Although it is a simple U.S. sales subsidiary, the explanation was that setup-stage costs are still being incurred.
Receivables and Payables
The increase is not from an accounting-standard change, but the scale of the increase versus the prior quarter still needs another check.
Production Base
The company is not operating an independent plant; it is currently producing through part of the Cheonan plant.
Sales Growth
The reason for higher India subsidiary sales remains an open question.
2. My Read and Next Checks
Official fact: In the call, BWA was described as a simple U.S. sales subsidiary, and Kort was described as producing through a rented portion of the Cheonan plant.
Interpretation: Subsidiary investment and early costs can be natural in a growth phase, but items that can affect cash flow and turnover, such as receivables and payables, need a clearer explanation.
Sources
- Original Naver Blog post: https://m.blog.naver.com/PostView.naver?blogId=star_of_self&logNo=223453898733